Alligator Bioscience to Participate in Upcoming Investor Conferences
Lund, Sweden, November 10, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences:
Redeye Life Science Day 2021
Location: Hybrid Event
Date: Thursday, November 11, 2021
Type: Live Presentation
Time: 16:30 – 16:50 CET
Live presentations can be viewed via the following link: www.redeye.se
H.C. Wainwright 7th Annual Israel Conference
Location: Virtual
Date: Monday, November 15, 2021
Type: Live Presentation & 1x1’s
Time: 14:00 – 14:30 CET
Inv€$tival Showcase 2021
Location: London and Virtual
Dates: November 8 - 15, 2021
Type: In Person 1x1’s, Nov 15, 2021
Jefferies HealthCare Conference
Location: London and Virtual
Date: November 16, 2021
Type: In Person 1x1’s
ØU Life Science Life Science Investor Konference Summit
Location: Copenhagen
Date: Wednesday, November 24, 2021
Type: Live Presentation & 1x1’s
Time: 15:50 - 16:20 CET
Presentation can be viewed via the following link: www.eventbrite.co.uk
All presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers to if you wish to attend or Julie Silber if you wish to schedule a meeting with Alligator.
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit http://www.alligatorbioscience.com.